Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.

Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.

AstraZeneca Head of Emerging Market Collaborations Ajay Gautam talks to PharmAsia News about the company’s R&D strategy and deals with local partners.